News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

CEVEC Again Successful in Challenge to Crucell N.V. (CRXL) Patent


1/14/2008 9:56:23 AM

Cologne, Germany, January 14, 2008 / b3c newswire / - CEVEC Pharmaceuticals GmbH, the specialist supplier for human expression technologies, today announced that an opposition to a patent owned by Crucell N.V., Leiden, Netherlands (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX), before the European Patent Office was again successful. This is the second time within a year that the Opposition Division of the European Patent Office (EPO) has restricted a patent on Crucell’s PER.C6 cell line.

Read at press release

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES